- Main
Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials
- Moser, Carlee B;
- Chew, Kara W;
- Giganti, Mark J;
- Li, Jonathan Z;
- Aga, Evgenia;
- Ritz, Justin;
- Greninger, Alexander L;
- Javan, Arzhang Cyrus;
- Ignacio, Rachel Bender;
- Daar, Eric S;
- Wohl, David A;
- Currier, Judith S;
- Eron, Joseph J;
- Smith, Davey M;
- Hughes, Michael D;
- Hosey, Lara;
- Roa, Jhoanna;
- Patel, Nilam;
- Aldrovandi, Grace;
- Murtaugh, William;
- Science, Frontier;
- Cooper, Marlene;
- Gutzman, Howard;
- Knowles, Kevin;
- Bosch, Ronald;
- Harrison, Linda;
- Erhardt, Bill;
- Adams, Stacey
- et al.
Published Web Location
https://doi.org/10.1093/infdis/jiad285Abstract
Most clinical trials evaluating coronavirus disease 2019 (COVID-19) therapeutics include assessments of antiviral activity. In recently completed outpatient trials, changes in nasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA levels from baseline were commonly assessed using analysis of covariance (ANCOVA) or mixed models for repeated measures (MMRM) with single imputation for results below assay lower limits of quantification (LLoQ). Analyzing changes in viral RNA levels with singly imputed values can lead to biased estimates of treatment effects. In this article, using an illustrative example from the ACTIV-2 trial, we highlight potential pitfalls of imputation when using ANCOVA or MMRM methods, and illustrate how these methods can be used when considering values
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-